The IRB's role in assessing the generalizability of non-NIH-funded clinical trials

IRB Ethics and Human Research

Volumn 20, Issue 2-3, 1998, Pages 1-5

  Weijer, Charles ^a,b,c  

^a MOUNT SINAI HOSPITAL   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c MOUNT SINAI HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

NEW DRUG;

AGE; ARTICLE; BIOMEDICAL AND BEHAVIORAL RESEARCH; DRUG INDUSTRY; ETHICS; FEMALE; FINANCIAL MANAGEMENT; FOOD AND DRUG ADMINISTRATION; GOVERNMENT; GOVERNMENT REGULATION; HEALTH CARE ORGANIZATION; HUMAN; HUMAN EXPERIMENT; METHODOLOGY; MINORITY GROUP; MISCELLANEOUS NAMED GROUPS; NATIONAL INSTITUTES OF HEALTH; NIH GUIDELINES; PATIENT SELECTION; PRACTICE GUIDELINE; PROFESSIONAL STANDARD; RESEARCH; RESEARCH SUBJECT; RISK; RISK ASSESSMENT; SOCIAL CONTROL; UNITED STATES; VULNERABLE POPULATION;

BIOMEDICAL AND BEHAVIORAL RESEARCH; NATIONAL INSTITUTES OF HEALTH; NIH GUIDELINES;

AGE FACTORS; DRUG INDUSTRY; DRUGS, INVESTIGATIONAL; ETHICAL REVIEW; ETHICS; ETHICS COMMITTEES; ETHICS COMMITTEES, RESEARCH; FEDERAL GOVERNMENT; FEMALE; FINANCIAL SUPPORT; FINANCING, GOVERNMENT; GOVERNMENT; GOVERNMENT REGULATION; GUIDELINES; HUMAN EXPERIMENTATION; HUMANS; MINORITY GROUPS; NATIONAL INSTITUTES OF HEALTH (U.S.); NONTHERAPEUTIC HUMAN EXPERIMENTATION; PATIENT SELECTION; PERSONS; RESEARCH; RESEARCH DESIGN; RESEARCH SUBJECTS; RISK; RISK ASSESSMENT; SOCIAL CONTROL, FORMAL; THERAPEUTIC HUMAN EXPERIMENTATION; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; VULNERABLE POPULATIONS; WOMEN;

EID: 0032009383     PISSN: 01937758     EISSN: None     Source Type: Journal    
DOI: 10.2307/3563554     Document Type: Article

References (19)

1. Department of Health and Human Services, and National Institutes of Health: NIH guidelines on the inclusion of women and minorities as subjects in clinical research. Federal Register 1994; 59:14508-13.
2. Weijer C: Evolving ethical issues in selection of subjects for clinical research. Cambridge Quarterly of Healthcare Ethics 1996; 5:334-45.
3. Cardon PV, Dommel FW, Truble RR: Injuries to research subjects: a survey of investigators. NEJM 1976; 295:650-4.
4. Zarafonetis CJD, Riley PA, Willis PW, et al.: Clinically significant adverse effects in a phase one testing program. Clinical Pharmacology and Therapeutics 1978; 24:127-32.
5. McCann DJ, Pettit JR: A report on adverse effects insurance for human subjects. In: President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research. Compensating for Research Injuries: the Ethical and Legal Implications of Programs to Redress Injuries Caused By Biomedical and Behavioral Research (Appendices). Washington, D.C.: Government Printing Office, 1982.
6. Arnold JD: Incidence of injury during clinical pharmacology research and indemnification of injured research subjects at the Quincy Research Center. In: President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research. Compensating for Research Injuries.
7. Levine RJ: The impact of HIV infection on society's perception of clinical trials. Kennedy Institute of Ethics Journal 1994; 4:93-8.
8. Merton V: The exclusion of pregnant, pregnable, and once pregnable people (aka women) from biomedical research. American Journal of Law and Medicine 1994; 19: 369-450.
9. Mastroianni AC, Faden R, Federman D: Women and Health Research: Ethical and Legal Issues of Including Women in Clinical Research (vol. 1). Washington, D.C.: National Academy Press, 1994:36-74.
10. Food and Drug Administration: Guidelines for the Study and evaluation of gender differences in the clinical evaluation of drugs. Federal Register 1993; 58:39406-16.
11. These are outlined in a letter to IRBs by Gary Ellis, Director of the Office for Protection from Research Risk, 25 April 1994.
12. 45 CFR 46; Revised 18 June 1991.
13. Office for the Protection from Research Risk: Protecting Human Research Subjects: Institutional Review Board Guidebook. Washington, D.C.: U.S. Government Printing Office, 1993.
14. Gurwitz JH, Col NF, Avorn J: The exclusion of the elderly and women from clinical trials in acute myocardial infarction. JAMA 1992; 268: 1417-61.
15. Yusuf S, Wittes J, Probstfield J, Tyroler HA: Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. JAMA 1991; 266:93-8.
16. Freedman B, Shapiro S: Ethics and statistics in clinical research: towards a more comprehensive examination. Journal of Statistical Planning and Inference 1994; 42:223-40.
17. Freedman B: Scientific value and validity as ethical requirements for research: a proposed explication. IRB 1987; 9(6):7-10.
18. Freedman B, Fuks A, Weijer C: Demarcating research and treatment: a systematic approach for the analysis of the ethics of clinical research. Clinical Research 1992; 40:653-60.
19. Freedman, B: Equipoise and the ethics of clinical research. NEJM 1987; 317:141-5.